Results from the POLO trial: Olaparib may delay cancer progression in metastatic pancreatic cancer patients with BRCA mutations.
Full article:

Note: On 12/27/19, the FDA approved olaparib for treatment of pancreatic cancer in people with a BRCA mutation based on the results of the POLO study.

The POLO clinical trial looks at whether the PARP inhibitor olaparib improves outcomes for those with metastatic pancreatic cancer after platinum-based chemotherapy.  (7/3/19) 

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following are treatment studies enrolling people diagnosed with pancreatic cancer:

The following are vaccine studies enrolling people with pancreatic cancer:

Other clinical trials for people with pancreatic cancer can be found here.

The following studies are looking at treatment for people with advanced solid tumors. 



FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.